|
SEQUENOM Sells 10 MassARRAY Systems, 5.3 Million SpectroCHIP Elements; Pfizer, Baylor College of Medicine Top List of New Customers SAN DIEGO, Oct. 2 /PRNewswire/ -- SEQUENOM(TM), Inc. (NASDAQ:SQNM) today announced the sale of 10 additional MassARRAY(TM) systems during the third quarter, raising the Company`s installed base of systems to 48. The MassARRAY system is used to analyze genes to determine their association to disease and to accelerate genetics-based diagnostics and drug development. Some of the new customers that have chosen SEQUENOM`s high-throughput technology include Pfizer; the Department of Molecular and Human Genetics, Baylor College of Medicine, Houston; Children`s Hospital Boston; Genome Institute of Singapore; the Institute of Biomedical Sciences, Academia Sinica; and the Partners HealthCare/Harvard Medical School Genotyping Center. In addition, the Sanger Centre and the National Institutes of Health (NIH) have each purchased additional systems. The additional NIH system has been placed at the National Institute of Arthritis and Musculoskeletal and Skin Diseases. SEQUENOM also announced that more than 5.3 million SpectroCHIP(TM) elements were sold during the third quarter, which represents a 28 percent increase from the previous quarter and a 134 percent increase from the first quarter. SpectroCHIPs serve as high-density launching pads for the analysis of biomolecules, such as DNA, for use with the MassARRAY system. "We are encouraged by the recent and continued strong growth of our Genomics business," said Toni Schuh, Ph.D., SEQUENOM`s President and Chief Executive Officer. "Along with the addition of high-profile customers such as Pfizer and Baylor College of Medicine, we are pleased to see high-throughput users like the Sanger Centre and the NIH using multiple systems on site. With these sales, SEQUENOM now has five customers that utilize multiple MassARRAY systems. We are also encouraged by our consumable sales, which have shown a steady increase every quarter since the commercialization of our MassARRAY technology." About SEQUENOM SEQUENOM is a genomics company with the tools, information and strategies for determining the medical impact of genes and genetic variations. Utilizing a novel population genetics approach, SEQUENOM is systematically identifying potential disease-related genes that affect the most significant portions of the overall population. This approach is possible due to the pinpoint accuracy and unique specificity of the Company`s MassARRAY system. By focusing on disease genes with a broad population impact, SEQUENOM expects to play a critical role in bringing new therapeutic products to the market while maximizing the return on drug development. SEQUENOM completed its merger with Gemini Genomics plc, a clinical genomics company, in September 2001. |
|
| aus der Diskussion: | Sequenom: Super Chance in nächster Zeit!!! Wie ist eure Meinung? |
| Autor (Datum des Eintrages): | francoir (03.10.01 13:06:07) |
| Beitrag: | 6 von 66 (ID:4553849) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |